Aristeia Capital’s Haemonetics HAE Stock Holding History

Aristeia Capital’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-36,500	Closed	-$4.05M	–	497
2021 Q1	$4.05M	Buy	+36,500	New	+$4.52M	0.08%	288

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

LCOV

London Company of Virginia Richmond, Virginia $16.2B AUM 17.5% 1-Year Est. Return

LCP

LGT Capital Partners Pfaeffikon, Switzerland $1.88B AUM 20.37% 1-Year Est. Return

Aristeia Capital's HAE Position: Q2 2021 in Review

Aristeia Capital sold out of Haemonetics (HAE) in Q2 2021, closing a stake of 36,500 shares — an estimated $4.05M sold.

Aristeia Capital first reported a position in HAE in Q1 2021 and held it in 1 quarter. The position peaked at $4.05M in Q1 2021. 258 funds tracked by Wall St. Rank hold HAE as of Q2 2021.

Aristeia Capital reported no remaining Haemonetics position as of Q2 2021 after selling out during the quarter.
Aristeia Capital sold 36,500 Haemonetics shares in Q2 2021, an estimated $4.05M.
Aristeia Capital first reported a position in Haemonetics in Q1 2021 and held it in 1 quarter.
Aristeia Capital's Haemonetics position peaked at $4.05M in Q1 2021.
258 funds tracked by Wall St. Rank held Haemonetics as of Q2 2021.

Based on Aristeia Capital's 13F filing for Q2 2021, filed 16 Aug 2021.